REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS
Clinical trials for REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS trials appear
Sign up with your email to follow new studies for REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to unmask lymphoma cells to the immune system
Disease control OngoingThis phase 2 trial is testing a combination of two drugs, TTI-622 and pembrolizumab, in about 10 adults with diffuse large B-cell lymphoma that has returned or not responded to prior treatment. TTI-622 is a fusion protein that blocks a "don't eat me" signal on cancer cells, while…
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 07:10 UTC
-
New combo therapy aims to boost immune attack on tough lymphomas
Disease control OngoingThis phase 2 trial tests whether adding varlilumab to nivolumab helps people with aggressive B-cell lymphomas that have returned or not responded to standard therapy. About 54 participants will receive either nivolumab alone or nivolumab plus varlilumab. The goal is to see if the…
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
Promising lymphoma combo study pulled before it even started
Disease control TerminatedThis study planned to test a combination of three drugs (rituximab, venetoclax, and bortezomib) in adults with a type of aggressive lymphoma that had come back or stopped responding to standard treatment. The goal was to see if the combination could shrink or control the cancer. …
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated May 04, 2026 16:31 UTC